Alzheimer's disease
Conditions
Interventions
Gold Standard:The AD group was divided into 6 stages according to the contents of the 2018 NIA-AA Biological Definition of Alzheimers disease research framework, that is, into 6 groups, each group =20
Index test:Human plasma Aß1-42, Aß1-40, p-Tau181, p-Tau217, NfL, GFAP were detected. The t
Sponsors
Sanbo Brain Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) All subjects were =18 years old. (2) The AD group met the diagnostic criteria of the NIA-AA Revised Draft Guidelines for the Diagnosis of Alzheimer's Disease (2023 edition) : the presence of any abnormal core AD biomarker, namely fluid Aß42/40, p-Tau181, p-Tau 217, amyloid PET, or Tau PET, combined with clinical diagnosis. (3) Complete medical history, scale, body fluid markers or imaging data can support the diagnosis of AD and the stage of cognitive function. (4) The healthy control group had no history of neuropsychiatric diseases, no manifestations of cognitive impairment and central nervous system diseases, and the core AD biomarkers were negative. (5) The subject himself or his family members sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) The subject's sample has severe hemolysis, lipemia or turbidity; (2) If patients take Aß and tau-related antibody drugs, the antibody drugs may combine with the tested substance and interfere with the test results, and the test can only be detected after A certain period of drug withdrawal, and the specific withdrawal period needs to be confirmed by clinicians according to pharmacokinetics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aß1-42/Aß1-40;p-Tau181;p-Tau217;NfL;GFAP;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactChen Shengyun
Sanbo Brain Hospital, Capital Medical University
Outcome results
None listed